biostudies-literatureGrunwald MRForma TherapeuticsIncyteRigelTakedaShireIncyte CorporationSunesis Pharmaceuticals, IncBMSTG Therapeutics, IncAlexion Pharmaceuticals, IncGenentech, IncSyntimmuneRocheJanssenCTINCI NIH HHSCelgene CorporationProtalexAstex Therapeutics219-225https://www.ebi.ac.uk/biostudies/studies/S-EPMC8895348biostudies-literatureUnknown20(4)<h4>Background</h4>Polycythemia vera (PV) is associated with increased blood cell counts, risk of thrombosis, and symptoms including fatigue and pruritus. National guidelines support the use of hydroxyurea (HU) in high-risk patients or those with some other clinical indication for cytoreduction.<h4>Patients and methods</h4>REVEAL is a prospective, observational study designed to collect data pertaining to demographics, disease burden, clinical management, patient-reported outcomes, and health care resource utilization of patients with PV in the United States. In this analysis, HU treatment patterns and outcomes were assessed from 6 months prior to enrollment to the time of discontinuation, death, or data cutoff.<h4>Results</h4>Of the 1381 patients who received HU for ≥ 3 months, the medianClinical lymphoma, myeloma & leukemiaTreatment Patterns and Blood Counts in Patients With Polycythemia Vera Treated With Hydroxyurea in the United States: An Analysis From the REVEAL Study.PMC8895348P30 CA054174Oh STKuter DJGrunwald MRBurke JMSavona MRColucci PParasuraman SMesa RStein BWalshauser MAGerds ATAltomare IParanagama DfalseTreatment Patterns and Blood Counts in Patients With Polycythemia Vera Treated With Hydroxyurea in the United States: An Analysis From the REVEAL Study.<h4>Background</h4>Polycythemia vera (PV) is associated with increased blood cell counts, risk of thrombosis, and symptoms including fatigue and pruritus. National guidelines support the use of hydroxyurea (HU) in high-risk patients or those with some other clinical indication for cytoreduction.<h4>Patients and methods</h4>REVEAL is a prospective, observational study designed to collect data pertaining to demographics, disease burden, clinical management, patient-reported outcomes, and health care resource utilization of patients with PV in the United States. In this analysis, HU treatment patterns and outcomes were assessed from 6 months prior to enrollment to the time of discontinuation, death, or data cutoff.<h4>Results</h4>Of the 1381 patients who received HU for ≥ 3 months, the median2020-01-01T00:00:00Z2020 Apr2025-04-18T12:11:44.079Z2025-04-06T21:51:15.207ZS-EPMC88953483206352710.1016/j.clml.2019.09.601